GLORIA

GEOMAR Library Ocean Research Information Access

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Zhao, Jue  (8)
  • 2020-2024  (8)
  • 1
    In: Movement Disorders, Wiley, Vol. 37, No. 3 ( 2022-03), p. 525-534
    Abstract: Frontotemporal lobar degeneration with tauopathy caused by MAPT ( microtubule‐associated protein tau ) mutations is a highly heterogenous disorder. The ability to visualize and longitudinally monitor tau deposits may be beneficial to understand disease pathophysiology and predict clinical trajectories. Objective The aim of this study was to investigate the cross‐sectional and longitudinal 18 F‐APN‐1607 positron emission tomography/computed tomography (PET/CT) imaging findings in MAPT mutation carriers. Methods Seven carriers of MAPT mutations (six within exon 10 and one outside of exon 10) and 15 healthy control subjects were included. All participants underwent 18 F‐APN‐1607 PET/CT at baseline. Three carriers of exon 10 mutations received follow‐up 18 F‐APN‐1607 PET/CT scans. Standardized uptake value ratio (SUVR) maps were obtained using the cerebellar gray matter as the reference region. SUVR values observed in MAPT mutation carriers were normalized to data from healthy control subjects. A regional SUVR z score ≥ 2 was used as the criterion to define positive 18 F‐APN‐1607 PET/CT findings. Results Although the seven study patients had heterogenous clinical phenotypes, all showed a significant 18 F‐APN‐1607 uptake characterized by high‐contrast signals. However, the anatomical localization of tau deposits differed in patients with distinct clinical symptoms. Follow‐up imaging data, which were available for three patients, demonstrated worsening trends in patterns of tau accumulation over time, which were paralleled by a significant clinical deterioration. Conclusions Our data represent a promising step in understanding the usefulness of 18 F‐APN‐1607 PET/CT imaging for detecting tau accumulation in MAPT mutation carriers. Our preliminary follow‐up data also suggest the potential value of 18 F‐APN‐1607 PET/CT for monitoring the longitudinal trajectories of frontotemporal lobar degeneration caused by MAPT mutations. © 2021 International Parkinson and Movement Disorder Society
    Type of Medium: Online Resource
    ISSN: 0885-3185 , 1531-8257
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2041249-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: npj Parkinson's Disease, Springer Science and Business Media LLC, Vol. 9, No. 1 ( 2023-05-17)
    Abstract: So far, over 20 causative genes of monogenic Parkinson’s disease (PD) have been identified. Some causative genes of non-parkinsonian entities may also manifest with parkinsonism mimicking PD. This study aimed to investigate the genetic characteristics of clinically diagnosed PD with early onset age or family history. A total of 832 patients initially diagnosed with PD were enrolled, of which, 636 were classified into the early-onset group and 196 were classified into the familial late-onset group. The genetic testing included the multiplex ligation-dependent probe amplification and next generation sequencing (target sequencing or whole-exome sequencing). The dynamic variants of spinocerebellar ataxia were tested in probands with family history. In the early-onset group, 30.03% of patients (191/636) harbored pathogenic/likely pathogenic (P/LP) variants in known PD-related genes ( CHCHD2 , DJ-1 , GBA (heterozygous) , LRRK2 , PINK1 , PRKN , PLA2G6 , SNCA and VPS35 ). Variants in PRKN were the most prevalent, accounting for 15.72% of the early-onset patients, followed by GBA (10.22%), and PLA2G6 (1.89%). And 2.52% (16/636) had P/LP variants in causative genes of other diseases ( ATXN3, ATXN2, GCH1, TH, MAPT, GBA (homozygous) ). In the familial late-onset group, 8.67% of patients (17/196) carried P/LP variants in known PD-related genes ( GBA (heterozygous), HTRA2, SNCA ) and 2.04% (4/196) had P/LP variants in other genes ( ATXN2, PSEN1, DCTN1 ). Heterozygous GBA variants (7.14%) were the most common genetic cause found in familial late-onset patients. Genetic testing is of vital importance in differential diagnosis especially in early-onset and familial PD. Our findings may also provide some clues to the nomenclature of genetic movement disorders.
    Type of Medium: Online Resource
    ISSN: 2373-8057
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 2819218-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Molecular Neuroscience, Springer Science and Business Media LLC, Vol. 70, No. 2 ( 2020-02), p. 246-253
    Type of Medium: Online Resource
    ISSN: 0895-8696 , 1559-1166
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2020
    detail.hit.zdb_id: 2071508-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Movement Disorders, Wiley, Vol. 36, No. 2 ( 2021-02), p. 442-448
    Abstract: There was a paucity of follow‐up studies in the disease progression of early‐onset PD patients with Parkin mutations ( Parkin ‐EOPD). Here we conducted a longitudinal study to investigate the progression of motor and cognitive features of Parkin ‐EOPD patients. Methods Genetic analysis was performed via target sequencing and multiplex ligation‐dependent probe amplification. Thirty patients carrying homozygous or compound heterozygous Parkin mutations with at least 2 follow‐up revisions were investigated as the Parkin ‐EOPD group. Fifty‐two patients with at least 2 follow‐up revisions, who did not have any known causative PD mutations, GBA or LRRK2 risk variants, a heterozygous Parkin mutation or 2 Parkin mutations without a segregation test, were defined as the genetically undefined EOPD (GU‐EOPD) group. A linear mixed‐effect model was implemented to evaluate longitudinal changes in motor symptoms and cognition. Results At baseline, the Parkin ‐EOPD group had a lower Unified Parkinson's Disease Rating Scale score (UPDRS‐III) (off‐medication) than the GU‐EOPD group, without significant differences in cognition. A longitudinal study showed the estimated progression rate per year (standard error) of the UPDRS‐III score (off‐medication) was lower in the Parkin ‐EOPD group (0.203 [0.3162] points per year) than in the GU‐EOPD group (1.056 [0.3001] points per year). The difference in the UPDRS‐III score rate between the 2 groups was 0.853 (0.4183) ( P = 0.042). The Parkin ‐EOPD group showed better maintenance of spatial processing ability compared with the GU‐EOPD group ( P = 0.027). Conclusion Parkin ‐EOPD patients showed a slower deterioration of motor symptoms and a better spatial processing ability than GU‐EOPD patients, which suggests that subtyping according to genetic features can help predict PD progression. © 2020 International Parkinson and Movement Disorder Society
    Type of Medium: Online Resource
    ISSN: 0885-3185 , 1531-8257
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2041249-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Frontiers Media SA ; 2020
    In:  Frontiers in Neurology Vol. 11 ( 2020-12-18)
    In: Frontiers in Neurology, Frontiers Media SA, Vol. 11 ( 2020-12-18)
    Abstract: Introduction: Mutations in the Parkin gene are the most common cause of autosomal recessive early-onset Parkinson's disease (PD). However, little is known about the quality of life (QoL) in Parkin -related PD. Here, we investigated the patterns of QoL in newly diagnosed Parkin -related PD patients. Methods: Newly diagnosed PD patients (diagnosis made within 12 months) who had an age of onset (AOO) below 40 and underwent a PD-related genetic testing, were recruited ( n = 148). Among them, 24 patients carried bi-allelic variants in Parkin (PD- Parkin ) and 24 patients did not have any known causative PD mutations, or risk variants (GU-EOPD). The clinical materials, relevant factors and determinants of QoL were analyzed. Results: PD- Parkin patients had a younger AOO ( p = 0.003) and longer disease duration ( p = 0.005). After adjustment for AOO and disease duration, more dystonia ( p = 0.034), and worse scores of non-motor symptoms including Beck depression inventory (BDI, p = 0.035), Epworth sleepiness scale (ESS, p = 0.044), and subdomains of depression/anxiety ( p = 0.015) and sleep disorders ( p = 0.005) in Non-motor symptoms questionnaire, were found in PD- Parkin comparing with GU-EOPD. PD- Parkin patients had poorer QoL (adjusted p = 0.045), especially in the mobility (adjusted p = 0.025), emotional well-being (adjusted p = 0.015) and bodily discomfort dimensions (adjusted p = 0.016). BDI scores ( p = 0.005) and ESS scores ( p = 0.047) were significant determinants of QoL in PD-Parkin . Conclusion: Newly diagnosed PD- Parkin patients showed worse QoL. More depression and excessive daytime sleepiness predicted worse QoL. For clinicians, management of depression and excessive daytime sleepiness is suggested to better improve QoL in patients with Parkin mutations.
    Type of Medium: Online Resource
    ISSN: 1664-2295
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2020
    detail.hit.zdb_id: 2564214-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Brain, Oxford University Press (OUP), Vol. 143, No. 11 ( 2020-11-01), p. 3374-3392
    Abstract: Idiopathic rapid eye movement sleep behaviour disorder (RBD) is now recognized as an early manifestation of α-synucleinopathies. Increasing experimental studies demonstrate that manipulative lesion or inactivation of the neurons within the sublaterodorsal tegmental nucleus (also known as the subcoeruleus nucleus in humans) can induce RBD-like behaviours in animals. As current RBD animal models are not established on the basis of α-synucleinopathy, they do not represent the pathological substrate of idiopathic RBD and thus cannot model the phenoconversion to Parkinson’s disease. The purpose of this study was therefore to establish an α-synucleinopathy-based RBD animal model with the potential to convert to parkinsonian disorder. To this end, we first determined the functional neuroanatomical location of the sublaterodorsal tegmental nucleus in wild-type C57BL/6J mice and then validated its function by recapitulating RBD-like behaviours based on this determined nucleus. Next, we injected preformed α-synuclein fibrils into the sublaterodorsal tegmental nucleus and performed regular polysomnographic recordings and parkinsonian behavioural and histopathological studies in these mice. As a result, we recapitulated RBD-like behaviours in the mice and further showed that the α-synucleinopathy and neuron degeneration identified within the sublaterodorsal tegmental nucleus acted as the neuropathological substrates. Subsequent parkinsonian behavioural studies indicated that the α-synucleinopathy-based RBD mouse model were not stationary, but could further progress to display parkinsonian locomotor dysfunction, depression-like disorder, olfactory dysfunction and gastrointestinal dysmotility. Corresponding to that, we determined α-synuclein pathology in the substantia nigra pars compacta, olfactory bulb, enteral neuroplexus and dorsal motor nucleus of vagus nerve, which could underlie the parkinsonian manifestations in mice. In conclusion, we established a novel α-synucleinopathy-based RBD mouse model and further demonstrated the phenoconversion of RBD to Parkinson’s disease in this animal model.
    Type of Medium: Online Resource
    ISSN: 0006-8950 , 1460-2156
    RVK:
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2020
    detail.hit.zdb_id: 1474117-9
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Frontiers Media SA ; 2021
    In:  Frontiers in Neurology Vol. 12 ( 2021-4-1)
    In: Frontiers in Neurology, Frontiers Media SA, Vol. 12 ( 2021-4-1)
    Abstract: Objective: We aimed to characterize the cognitive profiles in multiple system atrophy (MSA) and explore the cerebral metabolism related to the cognitive decline in MSA using 18 F-fluorodeoxyglucose ( 18 F-FDG) Positron Emission Tomography (PET). Methods: In this study, 105 MSA patients were included for cognitive assessment and 84 of them were enrolled for 18 F-FDG PET analysis. The comprehensive neuropsychological tests covered five main domains including execution, attention, memory, language, and visuospatial function. The cognitive statuses were classified to MSA with normal cognition (MSA-NC) and MSA with cognitive impairment (MSA-CI), including dementia (MSA-D), and mild cognitive impairment (MSA-MCI). With 18 F-FDG PET imaging, the cerebral metabolism differences among different cognitive statuses were analyzed using statistical parametric mapping and post-hoc analysis. Results: Among 84 MSA patients, 52 patients were found with MSA-CI, including 36 patients as MSA-MCI and 16 patients as MSA-D. In detail, the cognitive impairments were observed in all the five domains, primarily in attention, executive function and memory. In 18 F-FDG PET imaging, MSA-D and MSA-MCI patients exhibited hypometabolism in left middle and superior frontal lobe compared with MSA-NC ( p & lt; 0.001). The normalized regional cerebral metabolic rate of glucose (rCMRglc) in left middle frontal lobe showed relative accuracy in discriminating MSA-CI and MSA-NC [areas under the curve (AUC) = 0.750; 95%CI = 0.6391–0.8609]. Conclusions: Cognitive impairments were not rare in MSA, and the hypometabolism in frontal lobe may contribute to such impairments.
    Type of Medium: Online Resource
    ISSN: 1664-2295
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2021
    detail.hit.zdb_id: 2564214-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Phenomics, Springer Science and Business Media LLC, Vol. 3, No. 1 ( 2023-02), p. 22-33
    Type of Medium: Online Resource
    ISSN: 2730-583X , 2730-5848
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 3045731-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...